Clinical trial · Interventional
Chloroquine for Glioblastoma.
Adjuvant Chloroquine to the Conventional Treatment for Glioblastoma.
NCT04772846CI-TRIAL-00050357unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Adjuvant chloroquine to the conventional treatment for glioblastoma; A randomized, single-blind, placebo-controlled, phase I/II trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oral tablet | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Chloroquine group
- interventionNames
- Drug: Oral tablet
- type
- PLACEBO_COMPARATOR
- label
- Placebo drug group
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- Survival duration after surgery
- timeFrame
- Three years
Secondary outcomes (1)
- measure
- End-point evaluation, survival at three years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: Histologically confirmed glioblastoma Adequate hematologic, hepatic, and renal function Karnofsky performance status score ≥ 70% Life expectancy ≥ six weeks Exclusion Criteria: Abnormal severe un-controlled medical conditions
References
Publications (0)
Data not yet available
No reference posted for this study.